KOLOA, Hawaii — In this expert perspective from Hawaiian Eye 2025, Ashkan M. Abbey, MD, discusses an advancement in retinal vein occlusion treatment from 2024 and highlights a treatment in the pipeline for 2025.
Abbey said the approval of the Vabysmo prefilled syringe (faricimab, Genentech) for the treatment of retinal vein occlusion (RVO) added durability to some patients’ treatment. Faricimab is another option for RVO instead of adding a steroid to aflibercept or bevacizumab.
“Looking forward to 2025 now, we may have another great potent, durable anti-VEGF option coming out,